An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | MicrobiomeTrials← Back to trialsNCT06447025
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-01-25Est. Completion: 2027-01
Enrollment target: 85 participants Locations- University of California Los Angeles, Los Angeles, California, United States
- Fixel Institute for Neurological Disease, University of Florida Health, Gainesville, Florida, United States
- Morsani Center for Advanced Health Care, University of South Florida Health, Tampa, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- Uncommon Cures, Chevy Chase, Maryland, United States
- Clinilabs Drug Development, Corp., Eatontown, New Jersey, United States
- Ohio State University United States, Columbus, Ohio, United States
- Children's Hospital of the University of Pennsylvania (CHOP), Philadelphia, Pennsylvania, United States
Other microbiome trials you might be interested in
Friedreich Ataxia
In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been …
Philadelphia, United StatesEst. completion Jun 4, 2030
Friedreich Ataxia
In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The mai…
Los Angeles, United StatesCompleted Oct 31, 2019